Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age With Immunoglobulin G4-related Disease (IgG4-RD)
The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD), as well as to assess the safety and tolerability, of inebilizumab in pediatric participants with IgG4-RD.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Amgen Call Center
- Phone Number: 866-572-6436
- Email: medinfo@amgen.com
Study Locations
-
-
Ceará
-
Fortaleza, Ceará, Brazil, 60140-025
- Recruiting
- Centro Oncologia Leonardo Da Vinci
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brazil, 40110-060
- Recruiting
- Universidade Federal da Bahia - Hospital Universitario Professor Edgard Santos
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazil, 90035-903
- Recruiting
- Hospital de Clinicas de Porto Alegre
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100730
- Recruiting
- Peking Union Medical College Hospital
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 401122
- Recruiting
- Childrens Hospital of Chongqing Medical University
-
-
Hunan
-
Changsha, Hunan, China, 410000
- Recruiting
- The Second Xiangya Hospital of Central South University
-
-
-
-
-
Athens, Greece, 11527
- Recruiting
- General Children Hospital Panagioti and Aglaias Kyriakou
-
Athens, Greece, 11521
- Recruiting
- Euroclinic Children Hospital
-
-
-
-
-
Roma, Italy, 00165
- Recruiting
- IRCCS Ospedale Pediatrico Bambino Gesu
-
-
-
-
-
Warsaw, Poland, 02-637
- Recruiting
- Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher
-
Warsaw, Poland, 04-730
- Recruiting
- Instytut Pomnik-Centrum Zdrowia Dziecka
-
Wroclaw, Poland, 52-114
- Recruiting
- Szpital Specjalistyczny Im A Falkiewicza we Wroclawiu
-
-
-
-
Valencia
-
Valencia, Valencia, Spain, 46026
- Recruiting
- Hospital Universitari i Politecnic La Fe
-
-
-
-
-
Ankara, Turkey (Türkiye), 06100
- Recruiting
- Hacettepe Universitesi Tip Fakultesi Hastanesi
-
Istanbul, Turkey (Türkiye), 34098
- Recruiting
- Istanbul Universitesi Cerrahpasa Tip Fakultesi
-
Istanbul, Turkey (Türkiye), 34764
- Recruiting
- Umraniye Egitim ve Arastirma Hastanesi
-
-
-
-
Florida
-
Tampa, Florida, United States, 33612
- Recruiting
- University of South Florida - Carol and Frank Morsani Center for Advanced Health Care
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Recruiting
- University of North Carolina at Chapel Hill
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
- Recruiting
- University of Pittsburgh Medical Center Childrens Hospital of Pittsburgh
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Participants must weigh ≥ 17 kg to be eligible for enrollment.
- Participant has provided informed consent/assent before initiation of any study-specific activities/procedures. Participant's legally authorized representative has provided informed consent when the participant is legally too young to provide informed consent, and the participant has provided written assent based on local regulations and/or guidelines before any study-specific activities/procedures being initiated.
- Age 2 to < 18 years at the time of screening. For participants who reach the age of legal consent during the clinical study, notification will be required, and a new consent form must be signed by the participant for continuation in the study.
- Clinical diagnosis of IgG4-RD.
- Fulfillment of the 2019 American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) classification criteria as determined by the principal investigator (PI) at screening. Specifically, participants must meet the classification criteria entry requirements (including involvement of one of the following organs: pancreas, bile ducts/biliary tree, orbits, lungs, kidneys, lacrimal glands, major salivary glands, retroperitoneum, aorta, pachymeninges, or thyroid gland [Riedel's thyroiditis]), must not meet any of the classification criteria exclusions, and must achieve at least 20 classification criteria inclusion points.
- Receipt of all age-appropriate and locally-required vaccinations before screening.
- Participants requiring treatment in addition to or other than glucocorticoids (GCs) for IgG4-RD according to PI's assessment at screening.
- Participants who are on GCs for the treatment of IgG4-RD should remain on a stable dose for at least 2 weeks before enrollment (Day 1). Tapering post enrollment will be at PI's discretion.
Key Exclusion Criteria:
-
Participants with any of the following abnormal liver function tests in the presence of hepatobiliary IgG4-RD activity:
- aspartate aminotransferase (AST) > 10 × upper limit of normal (ULN)
- alanine aminotransferase (ALT) > 10 × ULN
- total bilirubin (TBL) > 5 × ULN Screening liver function tests may be repeated before Day 1 to permit abnormal values due to hepatobiliary IgG4-RD activity to respond to GC treatment.
-
Evidence of significant hepatic, renal, or metabolic dysfunction or significant hematological abnormality, including any of the following at screening (one repeat test may be conducted to confirm results within the same screening period):
- platelet count < 75000/μL (or < 75 × 109/L)
- absolute neutrophil count < 1200 cells/μL
- total Ig < 600 mg/dL
- CD4 T lymphocyte count < 300 cells/µL
- hemoglobin < 8 g/dL (or < 80 g/L).
-
Estimated glomerular filtration rate < 45 mL/min/1.73 m^2.
-
B-cell counts < one-half of the lower limit of normal (LLN) for age according to the central laboratory.
-
Diagnosed with a concurrent autoimmune disease that is uncontrolled or requires any prohibited medication (unless approved by the medical monitor).
-
Clinically significant serious active or chronic viral, bacterial, or fungal infection that requires treatment with anti-infectives, hospitalization, or, in the investigator's opinion, represents an additional risk to the participant, within 2 months before Day 1 of study.
-
Known history of congenital or acquired immunodeficiency (eg, due to human immunodeficiency virus [HIV] infection, splenectomy, immunosuppression-related or idiopathic T-cell deficiencies) that predisposes the participant to infection.
-
Positive test for chronic hepatitis B infection at screening, defined as either: (1) Positive hepatitis B surface antigen (HBsAg); or (2) Positive hepatitis B core antibody (anti-HBc) PLUS negative hepatitis B surface antibody (anti-HBs). Note: Participants with a positive anti-HBs only, or a positive anti-HBc plus positive anti-HBs and negative HBsAg, are eligible to enroll.
-
Receipt of any of the following before Day 1: alemtuzumab, total lymphoid irradiation, bone marrow transplant, T-cell vaccination therapy.
-
Receipt of any of the following within 2 months before Day 1: azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, cyclophosphamide, tocilizumab, satralizumab, eculizumab, and mitoxantrone.
-
Receipt of rituximab or any experimental B-cell depleting agent (eg, ocrelizumab, obinutuzumab, ofatumumab, inebilizumab), or any non-depleting B-cell-directed therapy (eg, belimumab), abatacept, within 6 months before screening unless B-cell counts have returned to ≥ one-half the LLN.
-
Receipt of any live or attenuated vaccine (administration of inactivated [killed] vaccine is acceptable) within 4 weeks before Day 1, Bacillus Calmette-Guérin vaccine within 1 year of screening, or blood transfusion within 4 weeks before screening or during screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Inebilizumab
Participants will receive Inebilizumab via intravenous (IV) infusion. |
Inebilizumab will be administered via IV infusion. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum Plasma Concentration (Cmax) of Inebilizumab
Time Frame: Up to Day 561
|
Up to Day 561
|
|
Area Under the Plasma Concentration-time Curve (AUC) of Inebilizumab
Time Frame: Up to Day 561
|
Up to Day 561
|
|
Clearance (CL) of Inebilizumab
Time Frame: Up to Day 561
|
Up to Day 561
|
|
Terminal Half-life (t½) of Inebilizumab
Time Frame: Up to Day 561
|
Up to Day 561
|
|
Volume of Distribution at Steady-state (Vss) of Inebilizumab
Time Frame: Up to Day 561
|
Up to Day 561
|
|
Change from Baseline in CD20+ B-cell Counts
Time Frame: Baseline and Day 561
|
Baseline and Day 561
|
|
Number of Participants Experiencing Adverse Events (AEs)
Time Frame: Up to Day 561
|
Up to Day 561
|
|
Number of Participants Experiencing Serious Adverse Events (SAEs)
Time Frame: Baseline up to Day 561
|
Baseline up to Day 561
|
|
Number of Participants Experiencing Events of Interest (EOIs)
Time Frame: Baseline up to Day 561
|
Baseline up to Day 561
|
|
Number of Participants Experiencing Clinically Significant Changes from Baseline in Laboratory Parameters
Time Frame: Baseline up to Day 561
|
Baseline up to Day 561
|
|
Number of Participants Experiencing Clinically Significant Changes from Baseline in Vital Signs
Time Frame: Baseline up to Day 561
|
Baseline up to Day 561
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Time-to-first Treated Flare Across 52 Weeks
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Percentage of Flare-free Participants Across 52 Weeks
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Annualized Flare Rate Across 52 Weeks
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Presence of Antidrug Antibodies (ADA) Before and After Initiation of Treatment
Time Frame: Day 1 to Day 561
|
Day 1 to Day 561
|
|
Percent Reduction from Baseline in Daily Glucocorticoid Dose at Week 52
Time Frame: Baseline and Week 52
|
Baseline and Week 52
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: MD, Amgen
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20240202
- 2025-520988-41-00 (Ctis)
- 2025 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD Sharing Time Frame
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD Sharing Access Criteria
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.